Collectively, these results suggest that a decrease in DRAK1 protein level is associated with paclitaxel resistance in cervical cancer cells and results in an increase in TRAF6 expression and TRAF6-mediated NF-κB activation, promoting tumorigenesis of paclitaxel-resistant cells. The gene discussed is STK17A; the disease is cervical carcinoma.